Knowing How We Know, in Medicine and in the Age of AI

Science is not just a pile of discoveries. It is a running argument about which questions to ask, which observations to trust, how much evidence is enough and when to change our minds. Medicine is where that argument carries the highest stakes. A wrong assumption can change a diagnosis. Weak evidence can steer a decision about a drug. An ignored safety signal can leave a patient with harm that cannot be undone, and misplaced confidence can reach thousands of people before anyone notices.

So the real question in medicine is not only what we know. It is how we know it, and whether what we know deserves our trust. That gap is the line between information and understanding, and between scientific maturity and plain certainty.

A strong trial still leaves questions

Picture a clinical trial with ten thousand patients and a statistically strong result. On paper, that is excellent evidence. Yet the questions keep coming. How were the patients chosen, and who was left out? Did the study run long enough to catch harm that shows up late? Did the outcome matter to patients, or was it simply easy to measure? Were the negative results reported in full? And will the findings hold for millions of real patients who differ in age, illness, other medicines, diet and lifestyle?

These questions do not throw out the research. They put it in its proper place. That is the real strength of a scientific mind, accepting the evidence while staying honest about its edges.

Approval is a beginning

When a drug is approved, our knowledge of it does not end. A new chapter opens. Once a medicine reaches wide use, rare side effects and patient groups that never appeared in the pre approval studies can come into view. This is why pharmacovigilance is far more than paperwork for collecting adverse event reports. It is how medical knowledge keeps correcting itself. A safe system is not one where no risk is known. It is one that can spot a risk the moment it appears, understand it and act on it.

The streetlight problem

There is a quiet trap in all of this. We lean toward what is easy to measure. What fits in a spreadsheet feels scientific. What belongs to human experience or messy observation gets treated as less serious. This is the old streetlight effect, searching for the keys where the light is best.

Take manufacturing. If tablet dissolution, assay and content uniformity stay inside specification batch after batch, comfort is natural. But a small drift in the process may not break any specification today and still lead to instability later. A system that only watches specifications can miss it. Specifications matter, but they are not reality itself. Three good batches tell you something useful about a process. Treating them as proof of its whole nature is a lapse in thinking.

The better questions go deeper. Where does variation come from? Which variables are critical? How do they interact? How does the process behave under different conditions? That is the spirit of quality by design, building quality into understanding instead of testing it at the end. It does not mean old regulatory rules are wrong. It means asking whether we use them for their purpose and within current science, or only because that is how it has always been done.

What AI adds to the problem

Artificial intelligence brings a new twist. A large language model can learn from millions of pages, research papers, regulatory documents and past decisions. But that does not free it from the assumptions and institutional habits buried inside them. If past decisions treated a certain idea as correct again and again, a model can repeat that pattern at great speed, even after the circumstances have moved on.

Here is the paradox. AI can gather and rearrange knowledge faster than any person, yet speed does not teach it the difference between knowledge and understanding. It can give you the best summary of the past. But real scientific progress often starts when someone asks what if we have been asking the wrong question all along. No document in a database answers that. It takes context, independent thinking and a critical eye. The true test for AI may not be how well it answers. It may be how many important questions it can show us that we have never asked.

From certainty to honest uncertainty

Imagine a drug with a clear overall benefit in its clinical data. A traditional analytical system asks how big the treatment effect is. A more mature system asks that, and then keeps going. Which patients are not benefiting? Is harm rising in a particular subgroup? Was follow up too short? Does the endpoint reflect a real clinical benefit? Is there a signal that missed statistical significance but still carries biological or clinical weight? Did the way the data was produced limit what it can tell us?

That is where AI can become an intellectual challenger instead of a calculator or a search engine. But it has to be built to highlight uncertainty, not to manufacture certainty. Scientific institutions need to do the same. They should record not only their conclusions but what they know, what they do not, which evidence is strong, which rests on thin support, which questions remain open and what new observation would change the answer. This does not weaken science. It strengthens it. Mature science does not put on a show of certainty. It names doubt, measures it and manages it.

Why human experience still matters

None of this makes human experience obsolete. It gives it a new role. An experienced pharmacist or manufacturing scientist can sense a small change in a process that routine data does not yet treat as significant. A clinician can notice a shift in a patient’s behaviour, symptoms or daily function that sits outside any algorithm’s threshold. Those observations are not proof, but waving them away is not wise either.

Intuition should not replace evidence. It is better seen as an early signal that evidence needs to follow. Insight raises the question, research tests it, data strengthens or weakens it and independent verification makes it reliable. That is the best partnership between people and machines. AI should extend our ability to see, ask and catch mistakes, not take our place. A system that only returns what is already known is good at retrieval. That is not the same as intelligence.

The point of it all

This brings us back to the plainest question. Why are we doing any of this? Regulatory science, clinical trials, quality by design, pharmacovigilance, real world evidence, big data and AI are all tools. The goal is safer, more effective and more suitable treatment for the patient.

If an AI system can summarise thousands of regulatory documents in seconds but overlooks a serious safety signal because it breaks from historical patterns, it is fast and not smart. If a manufacturing system catches a meaningful deviation before it crosses a specification, if a pharmacovigilance system separates a rare adverse event from the usual noise, if a regulatory framework makes room to test its own assumptions from time to time, then we are moving toward a system that does more than comply. We are moving toward one that genuinely learns.

A map, not a destination

In the future, a shortage of information will probably not be our biggest problem. The hard part will be sorting reliable knowledge, meaningful evidence and true understanding out of a flood of data. The best scientist of tomorrow may not be the one who remembers the most facts. It may be the one who knows what to trust, what to challenge, which gap to spot and when to say honestly that we do not know yet. That sentence is no weakness. It is a mark of scientific honesty.

Real progress in medicine comes when we treat our knowledge as a working map and not a final destination. Every new observation can redraw it, and every unexpected finding can open a door to something we had not reached. So the quality by design of the future will not only design product quality. It will need to design the quality of knowledge itself, a system where evidence travels with its limits, decisions travel with their uncertainty and intelligence travels with humility.

AI can give us remarkable speed. Big data can give us remarkable reach. Modern analytics can give us sharper sensitivity. But direction will still come from a very human question. What do we truly want to know, and if our current answer is wrong, how would we find out? That is where knowledge meets information, information meets understanding and understanding meets responsibility. In medicine, in the end, that responsibility is the most important knowledge we have.

The views expressed in this article are solely those of the author and do not necessarily reflect the views of The Opinion Desk.